Overview
Ramiven 150 mg contains Abemaciclib, a potent CDK4/6 inhibitor used in the management of HR-positive, HER2-negative advanced or metastatic breast cancer. It slows the growth of cancer cells by inhibiting key proteins involved in cell division. Ramiven is often prescribed in combination with endocrine therapies or as monotherapy in select cases.





